Course
Abstract
Accurate HbAlc measurement is paramount to diabetes diagnosis and long term therapeutic glycaemic control. Yet discordance between glycaemic control and measured HbAlc in actual practice remains a risk of erroneous clinical decisions or diabetic drug prescription, affecting patient outcomes. Haemoglobin variants have been shown to affect HbAlc values, as the variant haemoglobin glycation rate may differ from that of HbA. Yet this is missed in the mainstream of standardized separation or immunoassay HbAlc testing methods, where limitations in resolving hemoglobin variants or non-specificity in identifying glycated variants respectively remains a potential source of error. Increasing recognition of this issue is evident as recent American Diabetes Association guidelines recommend that HbAlc cannot be measured in individuals who are homozygous variants naturally lacking HbA.
Capiliary Electrophoresis (CE) based HbAic testing is a superior resolution charge-based separation method built on the premises of hemoglobinopathy screening, which overcomes poorly resolving protein fractions in traditional pressure driven column separation methods. As rising immigration increases complexity of patient haemoglobin genotypes in populations, HbAlc analysis with superior resolution is increasingly important for detection of highly probable yet elusive haemoglobinopathy backgrounds to explain discordant Alc results and safeguard against erroneous diagnosis. In this talk, the principles of Capillary Electrophoresis for HbAlc measurement will be thoroughly explained. Superior resolution capabilities of Capillary Electrophoresis leading to clearly defined haemoglobin fraction separation, ease of HbAlc testing operation and results interpretation will also be discussed.
Speaker: Dr. Ivan Lam (Scientific Affairs Manager, SEA & APAC Export, Sebia)
Co-organized by:
Grandtech Scientific
Sebia
-
-
-